HIF-1 Inhibitor YC-1 Reverses the Acquired Resistance of EGFR-Mutant HCC827 Cell Line with MET Amplification to Gefitinib

BACKGROUND: Acquired resistance occurred in the majority of nonsmall cell lung cancer (NSCLC) patients receiving epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) therapy, and this may be related to the activation of the HIF-1 pathway. Therefore, we examined the influence of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Qian, Zheng, Jisheng, Chen, Ming, Jiang, Na, Xu, Xianrong, Huang, Feihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946473/
https://www.ncbi.nlm.nih.gov/pubmed/33763171
http://dx.doi.org/10.1155/2021/6633867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946473/
https://www.ncbi.nlm.nih.gov/pubmed/33763171
http://dx.doi.org/10.1155/2021/6633867

Ejemplares similares